NEW YORK (GenomeWeb) – Transposagen announced today that it has licensed CRISPR/Cas9 intellectual property from the Broad Institute.
With the non-exclusive license agreement, Transposagen will be able to combine CRISPR/Cas9 genome editing technology with its Footprint-Free Gene Editing System. The combination allows for "precision gene editing without fear of undesired off-target effects," Transposagen CEO John Printen said in a statement.
Lexington, Kentucky-based Transposagen is commercializing gene editing technologies to aid both basic research and drug discovery. The firm has licensed piggyBac transposon technology for almost all commercial applications.